The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...

US-based biotech Eikon Therapeutics has raised $350.7m in funding to advance its portfolio of cancer candidates. The company’s lead asset, EIK1001, is a systemically administered Toll-like ...

MILLBRAE — Eikon Therapeutics has signed a lease that will enable the biotech company to both expand and shift its headquarters to a modern tech and life sciences campus in Millbrae. The biotech ...